Compare uniQure N.V. Ordinary Shares (QURE) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs T-Mobile Us Inc — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while T-Mobile Us Inc trades at $159.4 (market cap $164.91B). The key difference: T-Mobile Us Inc is far larger — about 111.4× uniQure N.V. Ordinary Shares's market cap, and T-Mobile Us Inc pays a 3.04% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and T-Mobile Us Inc for 84 Days on average.
| QURE | TMUS | |
|---|---|---|
Market Cap | $1.48B | $164.91B |
Volume | 2,488,780 | 5,684,850 |
Sector | Health | Media |
52-Week High | $70.59 | $230.06 |
52-Week Low | $9.03 | $148.58 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $728.62M | $281.53B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
T-Mobile US (TMUS) trades at $153.73, up 1.22% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $88.31B revenue in 2025, 11.45% net margin, and consistent earnings beats in recent quarters. Recent developments include a 15% dividend increase and participation in a satellite connectivity joint venture with major carriers. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a $221.75 consensus price target representing significant upside potential.
TMUS presents a compelling growth story with improving profitability and strategic initiatives, though investors face risks from $84.6B debt load and competitive pressures. The stock's current valuation at 16.08 P/E appears reasonable given earnings growth trajectory. Technical resistance at $154-158 levels may challenge near-term momentum, but strong institutional support and dividend growth support long-term bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
